Back
4D Molecular Therapeutics 10K Form
Sell
30
FDMT
4D Molecular Therapeutics
Last Price:
7.88
Seasonality Move:
106.87%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2021-03-25 | 10K | FDMT/4D Molecular Therapeutics Annual |
Receive FDMT News And Ratings
See the #1 stock for the next 7 days that we like better than FDMT
FDMT Financial Statistics
Sales & Book Value
| Annual Sales: | $20.72M |
|---|---|
| Cash Flow: | $-30.59M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $11.33 |
| Price / Book: | 0.71 |
Profitability
| EPS (TTM): | -2.30000 |
|---|---|
| Net Income (TTM): | $-109.89M |
| Gross Margin: | -- |
| Return on Equity: | -25.54% |
| Return on Assets: | -23.85% |
4D Molecular Therapeutics Earnings Forecast
Key 4D Molecular Therapeutics Financial Ratios
- The Research & Development expenses have been 468.54% of Revenue.
- The Net Earning history of FDMT is -486.59% of Total Revenues.
- Per Share Earnings over the last 7 years have been positive in 2 years.
4D Molecular Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | FDMT |
| CUSIP: | 35104E |
| Website: | 4dmoleculartherapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 28.48 |
| Quick Ratio: | 27.93 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
FDMT Technical Analysis vs Fundamental Analysis
Sell
30
4D Molecular Therapeutics (FDMT)
is a Sell
Is 4D Molecular Therapeutics a Buy or a Sell?
-
4D Molecular Therapeutics stock is rated a Sell
The current 4D Molecular Therapeutics [FDMT] share price is $8.08. The Score for FDMT is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.